- Report
- November 2025
- 198 Pages
Global
From €3148EUR$3,545USD£2,700GBP
€3498EUR$3,939USD£3,000GBP
- Report
- August 2026
- 370 Pages
Global
From €5194EUR$5,850USD£4,455GBP
- Report
- August 2026
- 186 Pages
Global
From €3148EUR$3,545USD£2,700GBP
€3498EUR$3,939USD£3,000GBP
- Report
- November 2025
- 183 Pages
Global
From €3996EUR$4,500USD£3,427GBP
- Report
- February 2026
- 250 Pages
Global
From €3987EUR$4,490USD£3,419GBP
- Report
- February 2026
- 250 Pages
Global
From €3987EUR$4,490USD£3,419GBP
- Report
- August 2026
- 373 Pages
Global
From €5194EUR$5,850USD£4,455GBP
- Report
- August 2026
- 380 Pages
Global
From €5194EUR$5,850USD£4,455GBP
- Report
- August 2026
- 282 Pages
Global
From €5194EUR$5,850USD£4,455GBP
- Report
- July 2026
- 180 Pages
Global
From €4218EUR$4,750USD£3,617GBP
- Report
- August 2026
- 110 Pages
Global
From €4218EUR$4,750USD£3,617GBP
- Report
- May 2026
- 146 Pages
Global
From €3507EUR$3,950USD£3,008GBP
- Report
- February 2026
- 171 Pages
Global
From €4306EUR$4,850USD£3,693GBP
- Report
- February 2025
- 315 Pages
Global
From €4261EUR$4,799USD£3,655GBP
- Report
- January 2025
- 456 Pages
Global
From €4395EUR$4,950USD£3,770GBP
- Report
- April 2025
- 125 Pages
United States
From €2886EUR$3,250USD£2,475GBP
- Report
- January 2024
- 200 Pages
Global
From €3685EUR$4,150USD£3,160GBP
- Report
- June 2025
- 400 Pages
Global
From €4394EUR$4,949USD£3,769GBP
- Book
- August 2021
- 312 Pages

Hepatocellular Carcinoma (HCC) is a type of cancer that originates in the liver. It is the most common form of liver cancer and is the third leading cause of cancer-related deaths worldwide. HCC is typically diagnosed in individuals with underlying liver diseases such as cirrhosis, hepatitis B or C, and non-alcoholic fatty liver disease. Treatment options for HCC include surgery, radiation therapy, chemotherapy, and targeted therapy.
The oncology market for HCC is highly competitive, with a number of companies offering treatments and therapies. These include AbbVie, Bristol-Myers Squibb, Merck, Novartis, Pfizer, Roche, and Takeda. Additionally, there are a number of smaller companies that are developing novel therapies for HCC, such as Aduro Biotech, ArQule, and Oncoceutics. Show Less Read more